Turn Therapeutics (TTRX)
Market Price (5/11/2026): $3.72 | Market Cap: $109.5 MilSector: Health Care | Industry: Biotechnology
Turn Therapeutics (TTRX)
Market Price (5/11/2026): $3.72Market Cap: $109.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -127% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.8 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1% High stock price volatilityVol 12M is 112% Key risksTTRX key risks include [1] a limited cash runway raising substantial "going concern" doubts and the need for potentially dilutive future financing, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -127% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.8 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1% |
| High stock price volatilityVol 12M is 112% |
| Key risksTTRX key risks include [1] a limited cash runway raising substantial "going concern" doubts and the need for potentially dilutive future financing, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Turn Therapeutics (TTRX) stock has lost about 10% since 1/31/2026 because of the following key factors:
1. Negative Market Reaction to Financing Terms.
Despite Turn Therapeutics securing a growth capital loan facility of up to $25 million from Avenue Capital Group in March 2026, with an initial $7 million funded, the market reacted with caution, as indicated by a -2.34% stock change on March 24, 2026. The financing, structured as a loan with the remaining $18 million contingent on achieving specific clinical milestones, likely highlighted the company's ongoing reliance on future positive trial data and potential debt obligations, rather than providing an unequivocal positive catalyst.
2. Persistent Operating Losses and Limited Cash Position.
Turn Therapeutics reported its full-year 2025 financial results on March 31, 2026, disclosing an earnings per share (EPS) of -$0.062 for Q4 2025. As of December 31, 2025, the company's cash and cash equivalents stood at $5.08 million, prior to receiving the initial $7 million tranche from the Avenue Capital financing. This continued unprofitability and relatively modest cash reserve, despite the new financing extending its operational runway, contributed to investor apprehension, leading to a -2.7% decline in the stock price the day after the earnings announcement.
Show more
1. Negative Market Reaction to Financing Terms.
Despite Turn Therapeutics securing a growth capital loan facility of up to $25 million from Avenue Capital Group in March 2026, with an initial $7 million funded, the market reacted with caution, as indicated by a -2.34% stock change on March 24, 2026. The financing, structured as a loan with the remaining $18 million contingent on achieving specific clinical milestones, likely highlighted the company's ongoing reliance on future positive trial data and potential debt obligations, rather than providing an unequivocal positive catalyst.
2. Persistent Operating Losses and Limited Cash Position.
Turn Therapeutics reported its full-year 2025 financial results on March 31, 2026, disclosing an earnings per share (EPS) of -$0.062 for Q4 2025. As of December 31, 2025, the company's cash and cash equivalents stood at $5.08 million, prior to receiving the initial $7 million tranche from the Avenue Capital financing. This continued unprofitability and relatively modest cash reserve, despite the new financing extending its operational runway, contributed to investor apprehension, leading to a -2.7% decline in the stock price the day after the earnings announcement.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -8.0% change in TTRX stock from 1/31/2026 to 5/10/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.12 | 3.79 | -8.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 29 | 29 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TTRX | -8.0% | |
| Market (SPY) | 3.6% | 20.4% |
| Sector (XLV) | -6.9% | 1.2% |
Fundamental Drivers
The -21.9% change in TTRX stock from 10/31/2025 to 5/10/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.85 | 3.79 | -21.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 29 | 29 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TTRX | -21.9% | |
| Market (SPY) | 5.5% | 18.2% |
| Sector (XLV) | 0.3% | 5.0% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TTRX | ||
| Market (SPY) | 30.4% | 15.6% |
| Sector (XLV) | 4.0% | 3.4% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| TTRX | ||
| Market (SPY) | 78.7% | 15.6% |
| Sector (XLV) | 13.0% | 3.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TTRX Return | - | - | - | - | -44% | -4% | -46% |
| Peers Return | -20% | -58% | 111% | 39% | 51% | -32% | 2% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| TTRX Win Rate | - | - | - | - | 33% | 60% | |
| Peers Win Rate | 42% | 33% | 53% | 47% | 52% | 28% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| TTRX Max Drawdown | - | - | - | - | -61% | -21% | |
| Peers Max Drawdown | -31% | -64% | -33% | -44% | -34% | -46% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARQT, DERM, MDXG, ORGO, VRCA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
TTRX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.7% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
TTRX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Turn Therapeutics (TTRX)
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.
AI Analysis | Feedback
Here are 1-2 brief analogies for Turn Therapeutics (TTRX):
- The Gore-Tex of drug formulation, with a unique platform to make active ingredients more effective.
- Like Moderna, but for drug delivery rather than new drug molecules, making existing active ingredients more potent and safer.
AI Analysis | Feedback
- PermaFusion™ Platform: A proprietary platform technology designed to enhance drug performance by enabling stable suspension of active pharmaceutical ingredients in oil-based carriers without emulsifiers.
- Hexagen™: An initial formulation developed using the PermaFusion platform that suspends antimicrobial/anti-inflammatory compounds in petrolatum, which has received three FDA clearances as a medical device but is not currently marketed.
- Dermatological Drug Candidates: Development programs focusing on topical treatments for dermatological diseases, including moderate to severe eczema and onychomycosis.
- Thermostable Intranasal Vaccines: A development program in partnership with a global nonprofit organization to create intranasal vaccines that do not require deep-freeze storage.
- Preclinical Therapeutic Candidates: Exploratory preclinical programs investigating applications of the PermaFusion platform for conditions such as herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma.
AI Analysis | Feedback
Based on the provided company description, Turn Therapeutics (TTRX) is a pharmaceutical and medical device development company that is not currently generating revenue from its products. The company explicitly states, "These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology."
Therefore, Turn Therapeutics does not currently have any major customers in the traditional sense of revenue-generating sales. As a development-stage company, its focus is on advancing its drug programs and technology.
AI Analysis | Feedback
nullAI Analysis | Feedback
Turn Therapeutics (TTRX) Management Team:Bradley Burnam, Chief Executive Officer
Bradley Burnam is the founder of Turn Therapeutics, which he initially formed as Global Health Solutions, LLC in 2015. His inspiration for establishing the company stemmed from a personal and severe multidrug-resistant infection, leading him to develop a topical ointment known as Hexagen. Prior to founding Turn Therapeutics, Mr. Burnam gained experience in medical device sales. He is recognized as a self-taught formulator and regulatory expert, having personally secured the company's first three FDA clearances.
Zuraiz Chaudhary, CPA, Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer
Zuraiz Chaudhary holds the titles of Interim Chief Financial Officer, Vice President of Finance, and Chief Accounting Officer at Turn Therapeutics. He has been identified in SEC filings with a date of service for Director of Finance/CFO as April 30, 2025.
Dr. Neil Ghodadra, MD, Chief Medical Officer, Board Director
Dr. Neil Ghodadra is a Board Certified Orthopedic Surgeon who joined Turn Therapeutics in Q3 2017. He is also the President and Owner of Neil Ghodadra MD Inc. since July 2011. Dr. Ghodadra specializes in minimally invasive, arthroscopic surgeries of the knee, shoulder, elbow, and hip, with extensive expertise in cartilage restoration. He graduated Magna Cum Laude from Duke University and with Honors from Duke Medical School, completing his residency at Rush Medical Center.
Andrew Scott, Vice President of Corporate Communications
Andrew Scott was appointed as Vice President of Corporate Communications in November 2025. He brings over 30 years of experience in capital markets and corporate finance. Before joining Turn Therapeutics, Mr. Scott served as a Managing Director of Investment Banking at ThinkEquity LLC and as Vice President of Business Development at Fortress Biosciences, Inc. Throughout his career, he has played a role in raising approximately $3 billion across various life-sciences transactions.
Martin Dewhurst, Board Director
Martin Dewhurst joined Turn Therapeutics' Board of Directors in January 2026. He possesses over 30 years of global leadership experience in the life sciences sector, with a significant focus on mergers and acquisitions. Mr. Dewhurst spent three decades at McKinsey & Company, where he co-led the firm's global life sciences practice and co-founded and led the McKinsey Health Institute. He currently serves as an advisor to GHO Capital, a healthcare specialist private equity firm, and PJT Partners, a global investment and M&A advisory bank, and is an external partner to Lightrock, a growth-stage impact investor, demonstrating a pattern of managing or advising companies backed by private equity firms.
AI Analysis | Feedback
Key Risks to Turn Therapeutics (TTRX)
- High-Risk, Lengthy, and Costly Drug Development and Regulatory Approval Process: Turn Therapeutics' primary focus is on the development of new drugs utilizing its PermaFusion platform. This endeavor involves extensive preclinical and clinical trials, which are inherently high-risk, time-consuming, and expensive with a significant likelihood of failure at any stage. Successfully navigating the stringent regulatory approval processes by agencies like the FDA for new drugs is a monumental challenge, and failure to secure approvals would severely impact the company's prospects.
- Lack of Current Revenue Generation and Dependence on External Financing: The company explicitly states that it is not currently generating revenue from its devices and is focused on drug development. As such, Turn Therapeutics is operating without a revenue stream and is entirely dependent on securing sufficient external capital to fund its ongoing research, development, and operational expenses. A failure to raise adequate financing could significantly impede its ability to continue operations and advance its drug programs.
AI Analysis | Feedback
nullAI Analysis | Feedback
Turn Therapeutics (TTRX) operates in the dermatological disease market, primarily focusing on treatments for moderate to severe eczema (atopic dermatitis) and onychomycosis. The addressable market sizes for their main products are as follows: * **Onychomycosis:** * The global onychomycosis market was estimated at approximately $3.81 billion in 2024 and is projected to reach $5.74 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4.7% from 2025 to 2033. Other estimates place the global market at $4.03 billion in 2025, expanding to approximately $6.41 billion by 2035 with a CAGR of 4.74% from 2026 to 2035. * In the U.S., the onychomycosis treatment market was valued at $1.6 billion in 2024 and is expected to reach $1.60 billion by 2032. Another source indicates the U.S. market demand for onychomycosis treatment is valued at $2.4 billion in 2026 and is forecasted to reach $3.8 billion by 2036, reflecting a CAGR of 4.7%. * **Moderate to Severe Eczema (Atopic Dermatitis):** * The global eczema market, encompassing the top 7 markets (U.S., EU4, U.K., and Japan), reached a value of $18.1 billion in 2024. This market is expected to reach $40.2 billion by 2035, exhibiting a CAGR of 7.57% during 2025-2035. Another projection for the overall atopic dermatitis market size is $19.38 billion in 2025, reaching $33.29 billion by 2031, growing at a CAGR of 9.5% from 2026 to 2031. * The U.S. market size for moderate-to-severe atopic dermatitis was approximately $7.1 billion in 2023.AI Analysis | Feedback
Expected Revenue Growth Drivers for Turn Therapeutics (TTRX) Over the Next 2-3 Years
- Commercial Partnerships in Advanced Wound Care: Turn Therapeutics anticipates generating near-term revenue in 2026 through its strategic partnership with Medline in the advanced wound care market. This collaboration is expected to expand the company's market presence and leverage Medline's extensive reach for commercialization.
- Commercialization of GX-03 for Moderate-to-Severe Atopic Dermatitis (Eczema): The company's lead clinical trial, a Phase 2 Randomized Controlled Trial (RCT) of GX-03 for moderate-to-severe atopic dermatitis, is on track to deliver both interim and topline data in the first half of 2026. Successful clinical outcomes and subsequent commercial execution of this program are considered pivotal for future revenue generation.
- Advancement of Onychomycosis Programs: Turn Therapeutics is actively progressing late-stage clinical programs for onychomycosis, aiming to develop a portfolio of potential best-in-class products in this therapeutic area. This focus on advancing these programs is a key component of its immediate strategic goals, indicating a potential revenue driver in the coming years.
- Expansion into Intranasal Vaccines: The company has expanded its pipeline to include an intranasal influenza vaccine candidate, with in-vivo and in-vitro studies scheduled to commence in the first quarter of 2026. This initiative is viewed as a significant expansion of Turn Therapeutics' addressable market and growth opportunities, leveraging its proprietary delivery technology for thermostable vaccines.
AI Analysis | Feedback
Capital Allocation Decisions for Turn Therapeutics (TTRX) Over the Last 3-5 Years
Turn Therapeutics (TTRX) has focused its capital allocation on funding its drug development programs, primarily through share issuances and strategic financing agreements, especially around its public listing on Nasdaq in October 2025.Share Repurchases
The company has not engaged in any share repurchases over the last five years, with its buyback yield consistently reported as 0%.Share Issuance
Turn Therapeutics undertook significant share issuances in connection with its public listing:- The company issued 17,900,000 shares during its Initial Public Offering (IPO), commencing trading on the Nasdaq Capital Market under the ticker TTRX on October 8, 2025.
- A registration statement on Form S-1 for the public listing of its common stock on Nasdaq became effective on September 30, 2025.
- From March 31, 2025, to June 27, 2025, Turn Therapeutics conducted a Regulation A offering, selling 41,805 shares of common stock at $11.65 per share, prior to a stock split.
- The company executed a 2-for-1 forward stock split of its common stock in connection with the effectiveness of its registration statement.
- As of February 19, 2026, the number of outstanding shares stood at 29.45 million, representing a 3.81% increase in one year.
Inbound Investments
- Turn Therapeutics secured an $85 million GEM Global Yield agreement, providing a flexible, on-demand financing mechanism designed to allow opportunistic capital access and reduce reliance on future equity offerings.
- The company opted for a direct listing structure for its Nasdaq debut, which allowed early shareholders to maintain their ownership positions by bypassing traditional IPO share issuance.
- Significant institutional shareholders include Millennium Management LLC, Wellington Shields & Co. LLC, XTX Topco Ltd, and Brown Brothers Harriman & Co.
Capital Expenditures
Turn Therapeutics has reported a 0% average for Capital Expenditures to Operating Cash Flow (CapEx/OCF) over the last five years.Trade Ideas
Select ideas related to TTRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.43 |
| Mkt Cap | 0.2 |
| Rev LTM | 226 |
| Op Inc LTM | -1 |
| FCF LTM | 17 |
| FCF 3Y Avg | -7 |
| CFO LTM | 27 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.7% |
| Rev Chg 3Y Avg | 11.7% |
| Rev Chg Q | 18.1% |
| QoQ Delta Rev Chg LTM | 4.1% |
| Op Inc Chg LTM | 55.2% |
| Op Inc Chg 3Y Avg | -17.5% |
| Op Mgn LTM | 0.8% |
| Op Mgn 3Y Avg | -14.8% |
| QoQ Delta Op Mgn LTM | 3.7% |
| CFO/Rev LTM | 6.0% |
| CFO/Rev 3Y Avg | -9.9% |
| FCF/Rev LTM | 3.3% |
| FCF/Rev 3Y Avg | -12.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 2.2 |
| P/Op Inc | 2.0 |
| P/EBIT | 1.0 |
| P/E | -9.2 |
| P/CFO | 7.6 |
| Total Yield | -1.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -5.6% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.2% |
| 3M Rtn | -26.3% |
| 6M Rtn | -28.5% |
| 12M Rtn | -24.4% |
| 3Y Rtn | -29.0% |
| 1M Excs Rtn | -7.8% |
| 3M Excs Rtn | -33.0% |
| 6M Excs Rtn | -35.6% |
| 12M Excs Rtn | -67.8% |
| 3Y Excs Rtn | -89.4% |
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2026 | -2.7% | 9.4% | 15.3% |
| 11/13/2025 | -7.0% | -35.7% | -30.0% |
| SUMMARY STATS | |||
| # Positive | 0 | 1 | 1 |
| # Negative | 2 | 1 | 1 |
| Median Positive | 9.4% | 15.3% | |
| Median Negative | -4.9% | -35.7% | -30.0% |
| Max Positive | 9.4% | 15.3% | |
| Max Negative | -7.0% | -35.7% | -30.0% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chaudhary, Zuraiz | See Remarks | Direct | Buy | 12122025 | 3.50 | 2,500 | 8,750 | 43,750 | Form |
| 2 | Golden, Arthur F | Direct | Buy | 11252025 | 3.44 | 9,868 | 33,946 | 208,471 | Form | |
| 3 | Golden, Arthur F | Direct | Buy | 11242025 | 2.87 | 20,532 | 58,927 | 145,607 | Form | |
| 4 | Chaudhary, Zuraiz | See Remarks | Direct | Buy | 11212025 | 3.29 | 1,000 | 3,290 | 32,900 | Form |
| 5 | Chaudhary, Zuraiz | See Remarks | Direct | Buy | 11212025 | 2.61 | 1,450 | 3,784 | 23,490 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.